サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1644167

疫学における人工知能の世界市場

Artificial Intelligence in Epidemiology

出版日
ページ情報
英文 172 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
疫学における人工知能の世界市場
出版日: 2025年01月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 172 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

疫学における人工知能の世界市場は2030年までに26億米ドルに達する見込み

2024年に6億8,560万米ドルと推定される疫学における人工知能の世界市場は、2024年から2030年にかけてCAGR 25.2％で成長し、2030年には26億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるクラウドベースの展開は、CAGR 24.7％を記録し、分析期間終了時には21億米ドルに達すると予測されます。ウェブベース展開セグメントの成長率は、分析期間中CAGR 27.1%と推定されます。

米国市場は推定1億8,020万米ドル、中国はCAGR23.9％で成長予測

米国の疫学における人工知能市場は、2024年に1億8,020万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4億130万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは23.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ22.9％と21.8％と予測されています。欧州では、ドイツがCAGR約17.4%で成長すると予測されています。

世界の疫学における人工知能市場- 主要動向と促進要因まとめ

AIは疫学と公衆衛生をどのように変革するか？

人工知能（AI）は、疾病の発生を予測、検出、管理する能力を強化することで、疫学の分野に革命をもたらしています。従来の疫学的手法は効果的ではあるが、急速に進展する健康危機に対応するために大量のデータを迅速に処理することに苦慮することが多いです。AIは、高度な機械学習アルゴリズム、自然言語処理（NLP）、予測分析を用いて膨大なデータセットをリアルタイムで分析することで、この課題に対処します。

AIシステムは、電子カルテ（EHR）、ソーシャルメディア、環境データなどの多様なデータソースを監視し、疾病発生の初期兆候を特定します。これらのツールは、新たな健康上の脅威を示すパターンや異常を検出し、より迅速な介入を可能にします。COVID-19パンデミックの際、AIはウイルス・トランスミッションの追跡、感染動向のモデル化、ワクチン開発の支援において重要な役割を果たしました。

アウトブレイクの検知にとどまらず、AIは様々な介入が公衆衛生の結果に与える影響をシミュレーションすることで、疾病モデリングに変革をもたらしつつあります。これらのシミュレーションは、政策立案者が疫病を管理し、資源を配分し、疾病の社会的影響を最小限に抑えるための効果的な戦略を設計するのに役立ちます。データ駆動型の意思決定を可能にすることで、AIは疫学の実践を根本的に再構築しています。

疫学におけるAIの採用を推進するものは何か？

疫学におけるAI導入の重要な原動力は、疾病発生の頻度と複雑性の増大です。世界化、都市化、気候変動は感染症の蔓延を助長しており、健康の脅威を監視し対応するための高度なツールが緊急に必要とされています。AIを搭載したプラットフォームはリアルタイムの監視機能を提供し、公衆衛生機関が発生を食い止めるために迅速に行動できるようにします。

ビッグデータの利用可能性が高まっていることも重要な要因です。医療機関は現在、EHR、ウェアラブル端末、ゲノム研究、ソーシャルメディアから膨大な量のデータにアクセスできます。AIシステムはこのデータを分析し、公衆衛生戦略に役立つ動向や相関関係を明らかにします。この能力は、新興疾病の動態を理解し、脆弱な集団を特定する上で特に価値があります。

さらに、ディープラーニングやデータ可視化などのAI技術の進歩により、疫学的洞察の利用しやすさと使いやすさが向上しています。AIツールは、地域の保健部門からWHOのような国際機関まで、あらゆるレベルの意思決定者に力を与えるユーザーフレンドリーなレポートや可視化を生成します。これらの要因は、現代の疫学の課題に取り組む上でAIの重要性が増していることを浮き彫りにしています。

AIは疾病予測と資源配分を改善できるか？

AIは、疫学の2つの重要な側面である疾病予測と資源配分において、ゲームチェンジャーとなることが証明されつつあります。AIモデルによる予測分析では、過去のデータとリアルタイムのデータを分析することで、疾病の発生を予測します。こうした予測により、保健当局は疾病の蔓延を予測し、予防接種キャンペーンや公衆啓発活動などの予防措置を実施することができます。

資源配分では、AIが予測された疾病負担に基づいて、医薬品、人員、資金の配分を最適化します。例えば、パンデミックの際には、AIツールがヘルスケア資源が最も必要とされるホットスポットを特定し、効率的かつ公平な対応を保証します。この機能により、無駄を最小限に抑え、最も必要な地域に確実にリソースを振り向けることができます。

AIはまた、様々な公衆衛生対策の有効性を洞察することで、介入戦略の精度を高めます。さまざまなシナリオをシミュレートすることで、AIは政策立案者が渡航制限や検疫措置などの介入の潜在的な結果を評価するのに役立ちます。こうした進歩により、公衆衛生上の課題を管理するための、より積極的で的を絞ったアプローチが可能になりつつあります。

疫学におけるAI市場の成長の促進要因は？

疫学における人工知能市場の成長は、公衆衛生を管理するためのテクノロジーへの依存の高まりを反映した、いくつかの重要な要因によって牽引されています。感染症の有病率の上昇と、強固な監視システムの世界のニーズは、主要な成長促進要因です。AIを搭載したプラットフォームはリアルタイムのモニタリングと分析を可能にし、発生対応と疾病管理を改善するタイムリーな洞察を提供します。

自然言語処理やディープラーニングを含むAIの技術的進歩は、疫学ツールの能力をさらに拡大しています。これらの技術革新は、複雑なデータセットの分析と実用的な洞察の生成を可能にし、医療機関での採用を促進しています。

ウェアラブルデバイスや健康アプリの利用増加などの消費者行動動向は、AI主導の疫学を支える貴重なリアルタイムの健康データを生み出しています。さらに、AIベースの健康イニシアチブに対する政府および国際的な資金援助は、公衆衛生機関がその能力を強化するために高度なツールに投資しているため、市場の成長を後押ししています。これらの要因は、AI技術の継続的な進化と相まって、疫学におけるAI市場の急速な拡大を後押ししており、現代の公衆衛生戦略の要として位置付けられています。

セグメント

展開（クラウドベース展開、ウェブベース展開）;用途（感染予測・予測用途、疾患・症候群サーベイランス用途）;最終用途（製薬・バイオテクノロジー企業最終用途、研究機関最終用途、政府・国家機関最終用途、その他最終用途）

調査対象企業の例（注目の42社）

  • Alphabet, Inc.
  • Bayer AG
  • Clarivate Analytics
  • Cognizant Technology Solutions Corporation
  • eClinicalWorks LLC
  • Epic Systems Corporation
  • Intel Corporation
  • Komodo Health
  • Koninklijke Philips NV
  • Microsoft Corporation

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP29256

Global Artificial Intelligence in Epidemiology Market to Reach US$2.6 Billion by 2030

The global market for Artificial Intelligence in Epidemiology estimated at US$685.6 Million in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 25.2% over the analysis period 2024-2030. Cloud-based Deployment, one of the segments analyzed in the report, is expected to record a 24.7% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Web-based Deployment segment is estimated at 27.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$180.2 Million While China is Forecast to Grow at 23.9% CAGR

The Artificial Intelligence in Epidemiology market in the U.S. is estimated at US$180.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$401.3 Million by the year 2030 trailing a CAGR of 23.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 22.9% and 21.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 17.4% CAGR.

Global Artificial Intelligence in Epidemiology Market - Key Trends & Drivers Summarized

How Is AI Transforming Epidemiology and Public Health?

Artificial Intelligence (AI) is revolutionizing the field of epidemiology by enhancing the ability to predict, detect, and manage disease outbreaks. Traditional epidemiological methods, while effective, often struggle to process large volumes of data quickly enough to respond to rapidly evolving health crises. AI addresses this challenge by using advanced machine learning algorithms, natural language processing (NLP), and predictive analytics to analyze vast datasets in real time.

AI systems monitor diverse data sources, such as electronic health records (EHRs), social media, and environmental data, to identify early signs of disease outbreaks. These tools detect patterns and anomalies that may indicate emerging health threats, enabling faster interventions. During the COVID-19 pandemic, AI played a critical role in tracking virus transmission, modeling infection trends, and supporting vaccine development efforts.

Beyond outbreak detection, AI is transforming disease modeling by simulating the impact of various interventions on public health outcomes. These simulations help policymakers design effective strategies for managing epidemics, allocating resources, and minimizing the societal impact of diseases. By enabling data-driven decision-making, AI is fundamentally reshaping the practice of epidemiology.

What Drives the Adoption of AI in Epidemiology?

The increasing frequency and complexity of disease outbreaks are significant drivers of AI adoption in epidemiology. Globalization, urbanization, and climate change are contributing to the spread of infectious diseases, creating an urgent need for advanced tools to monitor and respond to health threats. AI-powered platforms provide real-time surveillance capabilities, ensuring that public health agencies can act swiftly to contain outbreaks.

The growing availability of big data is another critical factor. Health organizations now have access to vast amounts of data from EHRs, wearable devices, genomic studies, and social media. AI systems analyze this data to uncover trends and correlations that inform public health strategies. This capability is particularly valuable in understanding the dynamics of emerging diseases and identifying vulnerable populations.

Additionally, advancements in AI technologies, such as deep learning and data visualization, are enhancing the accessibility and usability of epidemiological insights. AI tools generate user-friendly reports and visualizations that empower decision-makers at all levels, from local health departments to international organizations like the WHO. These factors highlight the growing importance of AI in addressing the challenges of modern epidemiology.

Can AI Improve Disease Prediction and Resource Allocation?

AI is proving to be a game-changer in disease prediction and resource allocation, two critical aspects of epidemiology. Predictive analytics powered by AI models forecast disease outbreaks by analyzing historical and real-time data. These forecasts enable health authorities to anticipate the spread of diseases and implement preventive measures, such as vaccination campaigns and public awareness initiatives.

In resource allocation, AI optimizes the distribution of medical supplies, personnel, and funding based on predicted disease burdens. For example, during pandemics, AI tools identify hotspots where healthcare resources are needed most, ensuring an efficient and equitable response. This capability minimizes waste and ensures that resources are directed to areas of greatest need.

AI also enhances the precision of intervention strategies by providing insights into the effectiveness of various public health measures. By simulating different scenarios, AI helps policymakers evaluate the potential outcomes of interventions, such as travel restrictions or quarantine measures. These advancements are enabling a more proactive and targeted approach to managing public health challenges.

What’s Driving the Growth of the AI in Epidemiology Market?

The growth in the Artificial Intelligence in Epidemiology market is driven by several key factors, reflecting the increasing reliance on technology to manage public health. The rising prevalence of infectious diseases and the global need for robust surveillance systems are major growth drivers. AI-powered platforms enable real-time monitoring and analysis, providing timely insights that improve outbreak response and disease control.

Technological advancements in AI, including natural language processing and deep learning, are further expanding the capabilities of epidemiological tools. These innovations enable the analysis of complex datasets and the generation of actionable insights, driving adoption among health organizations.

Consumer behavior trends, such as increased use of wearable devices and health apps, are generating valuable real-time health data that supports AI-driven epidemiology. Additionally, government and international funding for AI-based health initiatives are boosting market growth, as public health agencies invest in advanced tools to enhance their capabilities. These factors, coupled with the continuous evolution of AI technologies, are propelling the rapid expansion of the AI in Epidemiology market, positioning it as a cornerstone of modern public health strategy.

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence in Epidemiology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Deployment (Cloud-based Deployment, Web-based Deployment); Application (Infection Prediction & Forecasting Application, Disease & Syndromic Surveillance Application); End-Use (Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Alphabet, Inc.
  • Bayer AG
  • Clarivate Analytics
  • Cognizant Technology Solutions Corporation
  • eClinicalWorks LLC
  • Epic Systems Corporation
  • Intel Corporation
  • Komodo Health
  • Koninklijke Philips NV
  • Microsoft Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Economic Frontiers: Trends, Trials & Transformations
    • Artificial Intelligence in Epidemiology - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • AI-Driven Disease Modeling Spurs Growth in Predictive Epidemiological Solutions
    • Integration of AI in Genomic Surveillance Expands Addressable Market for Pathogen Monitoring
    • Real-Time AI Analytics Propel Growth in Early Outbreak Detection and Response
    • Demand for AI in Vaccine Development Strengthens Global Health Preparedness
    • Emerging Use of AI in Population Health Management Sets the Stage for Smarter Interventions
    • AI Models for Zoonotic Disease Prediction Highlight Opportunities for Preventive Measures
    • Integration of Big Data and AI Strengthens Business Case for Advanced Epidemiological Insights
    • AI for Early Identification of Antimicrobial Resistance Spurs Innovations in Public Health
    • Real-Time Monitoring of Global Disease Trends Drives Adoption of AI-Based Platforms
    • Global Push for Pandemic Preparedness Strengthens Case for AI-Powered Solutions
    • Demand for Faster Disease Forecasting Highlights Market Potential for AI Applications
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Artificial Intelligence in Epidemiology Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Artificial Intelligence in Epidemiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cloud-based Deployment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Cloud-based Deployment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Web-based Deployment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Web-based Deployment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Infection Prediction & Forecasting Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Infection Prediction & Forecasting Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Disease & Syndromic Surveillance Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Disease & Syndromic Surveillance Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Research Labs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Research Labs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Government & State Agencies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Government & State Agencies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Artificial Intelligence in Epidemiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Deployment - Cloud-based Deployment and Web-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Artificial Intelligence in Epidemiology by Deployment - Percentage Breakdown of Value Sales for Cloud-based Deployment and Web-based Deployment for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Application - Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Artificial Intelligence in Epidemiology by Application - Percentage Breakdown of Value Sales for Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by End-Use - Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Artificial Intelligence in Epidemiology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Deployment - Cloud-based Deployment and Web-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Artificial Intelligence in Epidemiology by Deployment - Percentage Breakdown of Value Sales for Cloud-based Deployment and Web-based Deployment for the Years 2025 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Application - Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Artificial Intelligence in Epidemiology by Application - Percentage Breakdown of Value Sales for Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by End-Use - Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Artificial Intelligence in Epidemiology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Artificial Intelligence in Epidemiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Deployment - Cloud-based Deployment and Web-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan 6-Year Perspective for Artificial Intelligence in Epidemiology by Deployment - Percentage Breakdown of Value Sales for Cloud-based Deployment and Web-based Deployment for the Years 2025 & 2030
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Application - Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Artificial Intelligence in Epidemiology by Application - Percentage Breakdown of Value Sales for Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by End-Use - Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Artificial Intelligence in Epidemiology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Artificial Intelligence in Epidemiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Deployment - Cloud-based Deployment and Web-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China 6-Year Perspective for Artificial Intelligence in Epidemiology by Deployment - Percentage Breakdown of Value Sales for Cloud-based Deployment and Web-based Deployment for the Years 2025 & 2030
    • TABLE 40: China Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Application - Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Artificial Intelligence in Epidemiology by Application - Percentage Breakdown of Value Sales for Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by End-Use - Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Artificial Intelligence in Epidemiology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Artificial Intelligence in Epidemiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe 6-Year Perspective for Artificial Intelligence in Epidemiology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Deployment - Cloud-based Deployment and Web-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Artificial Intelligence in Epidemiology by Deployment - Percentage Breakdown of Value Sales for Cloud-based Deployment and Web-based Deployment for the Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Application - Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Artificial Intelligence in Epidemiology by Application - Percentage Breakdown of Value Sales for Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by End-Use - Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Artificial Intelligence in Epidemiology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • Artificial Intelligence in Epidemiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 52: France Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Deployment - Cloud-based Deployment and Web-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: France 6-Year Perspective for Artificial Intelligence in Epidemiology by Deployment - Percentage Breakdown of Value Sales for Cloud-based Deployment and Web-based Deployment for the Years 2025 & 2030
    • TABLE 54: France Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Application - Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Artificial Intelligence in Epidemiology by Application - Percentage Breakdown of Value Sales for Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by End-Use - Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Artificial Intelligence in Epidemiology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Artificial Intelligence in Epidemiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 58: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Deployment - Cloud-based Deployment and Web-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Germany 6-Year Perspective for Artificial Intelligence in Epidemiology by Deployment - Percentage Breakdown of Value Sales for Cloud-based Deployment and Web-based Deployment for the Years 2025 & 2030
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Application - Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Artificial Intelligence in Epidemiology by Application - Percentage Breakdown of Value Sales for Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by End-Use - Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Artificial Intelligence in Epidemiology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 64: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Deployment - Cloud-based Deployment and Web-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Italy 6-Year Perspective for Artificial Intelligence in Epidemiology by Deployment - Percentage Breakdown of Value Sales for Cloud-based Deployment and Web-based Deployment for the Years 2025 & 2030
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Application - Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Artificial Intelligence in Epidemiology by Application - Percentage Breakdown of Value Sales for Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by End-Use - Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Artificial Intelligence in Epidemiology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Artificial Intelligence in Epidemiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 70: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Deployment - Cloud-based Deployment and Web-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: UK 6-Year Perspective for Artificial Intelligence in Epidemiology by Deployment - Percentage Breakdown of Value Sales for Cloud-based Deployment and Web-based Deployment for the Years 2025 & 2030
    • TABLE 72: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Application - Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Artificial Intelligence in Epidemiology by Application - Percentage Breakdown of Value Sales for Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by End-Use - Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Artificial Intelligence in Epidemiology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Deployment - Cloud-based Deployment and Web-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 6-Year Perspective for Artificial Intelligence in Epidemiology by Deployment - Percentage Breakdown of Value Sales for Cloud-based Deployment and Web-based Deployment for the Years 2025 & 2030
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Application - Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Artificial Intelligence in Epidemiology by Application - Percentage Breakdown of Value Sales for Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by End-Use - Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Artificial Intelligence in Epidemiology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Artificial Intelligence in Epidemiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Deployment - Cloud-based Deployment and Web-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Epidemiology by Deployment - Percentage Breakdown of Value Sales for Cloud-based Deployment and Web-based Deployment for the Years 2025 & 2030
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Application - Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Epidemiology by Application - Percentage Breakdown of Value Sales for Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by End-Use - Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Epidemiology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Deployment - Cloud-based Deployment and Web-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of World 6-Year Perspective for Artificial Intelligence in Epidemiology by Deployment - Percentage Breakdown of Value Sales for Cloud-based Deployment and Web-based Deployment for the Years 2025 & 2030
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by Application - Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Artificial Intelligence in Epidemiology by Application - Percentage Breakdown of Value Sales for Infection Prediction & Forecasting Application and Disease & Syndromic Surveillance Application for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Epidemiology by End-Use - Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Artificial Intelligence in Epidemiology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Labs End-Use, Government & State Agencies End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION